[1] Graham AJ,Shrive FM,Ghali WA,et al. Defining the optimal treatment of locally advanced esophageal cancer: a systematic review and decision analysis[J]. Ann Thorac Surg,2007,83:1257-1264. [2] Pennathur A,Zhang J,Chen H,et al. The"best operation" for esophageal cancer[J]? Ann Thorac Surg,2010,89:2163-2167. [3] Hingorani ML,Crosby T,Maraveyas A,et al. Neoadjuvant chemoradiotherapy for resectable oesophageal and gastro-oesophageal junction cancer—do we need another randomised trial[J]? Clin Oncol(R Coll Radiol),2011,23:696-705. [4] Chen SB,Weng HR,Wang G,et al. Prognostic factors and outcome for patients with esophageal squamous cell carcinoma underwent surgical resection alone: evaluation of the seventh edition of the American Joint Committee on Cancer staging system for esophageal squamous cell carcinoma. J Thorac Oncol,2013,8:495-501. [5] Sgourakis G,Gockel I,Lang H. Endoscopic and surgical resection of T1a/T1b esophageal neoplasms: a systematic review[J]. World J Gastroenterol,2013,19:1424-1437. [6] Bedenne L,Michel P,Bouche O,et al. Chemoradiation followed by surgery compared with chemoradiation alone in squamous cancer of the esophagus: FFCD 9102[J]. J Clin Oncol,2007,25:1160-1168. [7] Chiu PW,Chan AC,Leung SF,et al. Multicenter prospective randomized trial comparing standard esophagectomy with chemoradiotherapy for treatment of squamous esophageal cancer: early results from the Chinese University Research Group for Esophageal Cancer(CURE)[J].J Gastrointest Surg,2005,9:794-802. [8] Rawat S,Kumar G,Kakria A,et al. Chemoradiotherapy in the management of locally advanced squamous cell carcinoma esophagus: is surgical resection required[J]? J Gastrointest Cancer,2013,44:277-284. [9] Ando N,Ozawa S,Kitagawa Y,et al. Improvement in the results of surgical treatment of advanced squamous esophageal carcinoma during 15 consecutive years[J]. Ann Surg,2000,232:225-232. [10] Cao XF,He XT,Ji L,et al. Effects of neoadjuvant radiochemotherapy on pathological staging and prognosis for locally advanced esophageal squamous cell carcinoma[J]. Dis Esophagus,2009,22:477-481. [11] Tepper J,Krasna MJ,Niedzwiecki D,et al. Phase Ⅲ trial of trimodality therapy with cisplatin,fluorouracil,radiotherapy,and surgery compared with surgery alone for esophageal cancer: CALGB 9781[J]. J Clin Oncol,2008,26:1086-1092. [12] Sjoquist KM,Burmeister BH,Smithers BM,et al. Survival after neoadjuvant chemotherapy or chemoradiotherapy for resectable oesophageal carcinoma: an updated meta-analysis[J]. Lancet Oncol,2011,12:681-692. [13] van Hagen P,Hulshof MC,van Lanschot JJ,et al. Preoperative chemoradiotherapy for esophageal or junctional cancer[J]. N Engl J Med,2012,366:2074-2084. [14] Sjoquist KM,Burmeister BH,Smithers BM,et al. Survival after neoadjuvant chemotherapy or chemoradiotherapy for resectable oesophageal carcinoma: an updated meta-analysis[J]. Lancet Oncol,2011,12:681-692. [15] Urba SG,Orringer MB,Turrisi A,et al. Randomized trial of preoperative chemoradiation versus surgery alone in patients with locoregional esophageal carcinoma[J]. J Clin Oncol,2001,19:305-313. [16] Taketa T,Xiao L,Sudo K,et al. Propensity-based matching between esophagogastric cancer patients who had surgery and who declined surgery after preoperative chemoradiation[J]. Oncology,2013,85:95-99. [17] Stahl M,Stuschke M,Lehmann N,et al. Chemoradiation with and without surgery in patients with locally advanced squamous cell carcinoma of the esophagus[J]. J Clin Oncol,2005,23:2310-2317. [18] Teoh AY,Chiu PW,Yeung WK,et al. Long-term survival outcomes after definitive chemoradiation versus surgery in patients with resectable squamous carcinoma of the esophagus: results from a randomized controlled trial[J]. Ann Oncol,2013,24:165-171. [19] Steyerberg EW,Neville BA,Koppert LB,et al. Surgical mortality in patients with esophageal cancer: development and validation of a simple risk score[J]. J Clin Oncol,2006,24:4277-4284. [20] Courrech -Staal EF,Aleman BM,Boot H,et al. Systematic review of the benefits and risks of neoadjuvant chemoradiation for oesophageal cancer[J]. Br J Surg,2010,97:1482-1496. [21] Wang KL,Wu TT,Choi IS,et al. Expression of epidermal growth factor receptor in esophageal and esophagogastric junction adenocarcinomas: association with poor outcome[J].Cancer,2007,109:658-667. [22] Ruhstaller T,Pless M,Dietrich D,et al. Cetuximab in combination with chemoradiotherapy before surgery in patients with resectable,locally advanced esophageal carcinoma: a prospective,multicenter phase ⅠB/Ⅱ trial(SAKK 75/06)[J]. J Clin Oncol,2011,29:626-631. [23] De Vita F,Orditura M,Martinelli E,et al. A multicenter phase Ⅱ study of induction chemotherapy with FOLFOX-4 and cetuximab followed by radiation and cetuximab in locally advanced oesophageal cancer[J]. Br J Cancer,2011,104:427-432. [24] Li G,Hu W,Wang J,et al. Phase Ⅱ study of concurrent chemoradiation in combination with erlotinib for locally advanced esophageal carcinoma[J]. Int J Radiat Oncol Biol Phys,2010,78:1407-1412. [25] Hurt CN,Nixon LS,Griffiths GO,et al. SCOPE1: a randomised phase Ⅱ/Ⅲ multicentre clinical trial of definitive chemoradiation,with or without cetuximab,in carcinoma of the oesophagus[J].BMC Cancer,2011,11:466-476. [26] D′Journo XB,Michelet P,Dahan L,et al. Indications and outcome of salvage surgery for oesophageal cancer[J]. Eur J Cardiothorac Surg,2008,33:1117-1123. [27] Geh JI,Bond SJ,Bentzen SM,et al. Systematic overview of preoperative(neoadjuvantneoadjuvant) chemoradiotherapy trials in oesophageal cancer: evidence of a radiation and chemotherapy dose response[J]. Radiother Oncol,2006,78:236-244. [28] Minsky BD,Pajak TF,Ginsberg RJ,et al. INT 0123(Radiation Therapy Oncology Group 94-05) phase Ⅲ trial of combined-modality therapy for esophageal cancer: high-dose versus standard-dose radiation therapy[J]. J Clin Oncol,2002,20:1167-1174. [29] Wieder HA,Brucher BL,Zimmermann F,et al. Time course of tumor metabolic activity during chemoradiotherapy of esophageal squamous cell carcinoma and response to treatment[J]. J Clin Oncol,2004,22:900-908. [30] Suzuki A,Xiao L,Hayashi Y,et al. Prognostic significance of baseline positron emission tomography and importance of clinical complete response in patients with esophageal or gastroesophageal junction cancer treated with definitive chemoradiotherapy[J].Cancer,2011,117:4823-4833. [31] Han D,Yu J,Yu Y,et al. Comparison of 18F-fluorothymidine and 18F-fluorodeoxyglucose PET/CT in delineating gross tumor volume by optimal threshold in patients with squamous cell carcinoma of thoracic esophagus[J]. Int J Radiat Oncol Biol Phys,2010,76:1235-1241. [32] Welsh J,Settle SH,Amini A,et al. Failure patterns in patients with esophageal cancer treated with definitive chemoradiation[J]. Cancer,2012,118:2632-2640. [33] Ruppert BN,Watkins JM,Shirai K,et al. Cisplatin/irinotecan versus carboplatin/paclitaxel as definitive chemoradiotherapy for locoregionally advanced esophageal cancer[J]. Am J Clin Oncol,2010,33:346-352. [34] Conroy T,Yataghene Y,Etienne PL,et al. Phase Ⅱ randomised trial of chemoradiotherapy with FOLFOX4 or cisplatin plus fluorouracil in oesophageal cancer[J].Br J Cancer,2010,103:1349-1355. [35] Conroy T,Galais MP,Raoul JC,et al. Phase Ⅲ randomized trial of definitive chemoradiotherapy(CRT) with FOLFOX or cisplatin and fluorouracil in esophageal cancer(EC): final results of the PRODIGE 5/ACCORD 17 trial(abstract)[J]. J Clin Oncol,2012,30 Suppl: abstr LBA4003.
2014, Vol. 23 
